Denali Therapeutics Inc. (DNLI) News
Follow Denali Therapeutics Inc. (DNLI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Denali Therapeutics Q2 2026 Earnings Call Transcript
On Thursday, Denali Therapeutics (NASDAQ: DNLI ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and
LIVE | Oct 12, 2026, 11:55 AM UTC
L
These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right. — Barrons.com
By Mackenzie TatananniFrom speculation over mergers and acquisitions to the hype surrounding clinical readouts, it seems biotechnology stocks are all the rage this year.The iShares Biotechnology exchange-traded fund has
NEWS | Sep 23, 2026, 05:45 AM UTC
L
DNLI: AVLAYAH's launch validates a brain-targeted biologics platform, driving pipeline and global expansion
Competition in blood-brain barrier therapies is intensifying, driving innovation and benefiting patients. AVLAYAH's launch validates the TransportVehicle platform, enabling expansion into new indications and global marke
NEWS | Sep 14, 2026, 09:52 PM UTC
L
DNLI: Avlayah's launch validates a platform poised for global expansion and broad neurotherapeutic impact
Competition, especially from China, is accelerating innovation in blood-brain barrier therapies. Avlayah's launch validates the platform, with rapid U.S. uptake and global expansion planned. The pipeline includes promisi
GEOPOLITICS | Sep 14, 2026, 09:07 PM UTC
L
DNLI points to AVYLAH launch for Hunter syndrome and broader pipeline
DNLI says it is leveraging its validated platform and capital base to advance a broad pipeline, highlighted by the AVYLAH launch for Hunter syndrome and multiple enzyme replacement therapies. Clinical and biomarker reado
EQUITY | Sep 09, 2026, 03:36 PM UTC
L
DNLI cites strong AVLAYAH launch and pipeline progress
Denali Therapeutics highlighted a strong AVLAYAH launch, robust pipeline progress, and global expansion plans, with key program data readouts expected in 2027–2028. Strategy centers on a multi-product enzyme franchise an
EQUITY | Sep 09, 2026, 02:41 PM UTC
L
DNLI Unwarranted Selloff in Sympathy to BIIB's Tau ASO for Alzheimer's; raise PT to $35 from $31 @ DBAB
DNLI Unwarranted Selloff in Sympathy to BIIB's Tau ASO for Alzheimer's; raise PT to $35 from $31 @ DBAB
EQUITY | Jul 16, 2026, 12:10 PM UTC